Abstract
Background: Epilepsy affects about 70 million people worldwide, nearly 90% of whom live in developing countries. Epilepsy is surrounded by myths and stigma in these countries. Discrimination and social stigmatization are difficult obstacles for patients to overcome. Knowledge, attitudes and practices towards epilepsy are often inadequate, even sometimes totally false and then dangerous.
Methods: The goal was to present the situation and analyse the determinants of using antiepileptic drugs in developing countries. Results: The treatment gap exceeds 75% in most low-income countries, and could be even higher in rural areas. Reasons for that are low accessibility, availability, and/or affordability, lack of trained medical personnel and the associated beliefs and stigma. The interactions between drugs or due to other factors, such as malnutrition, are frequent. A long-lasting treatment is not usual for populations in developing countries due to cultural beliefs. The traditional healers are the first ones consulted in such a context, then delaying the entry in the “modern” medical care system. Conclusion: Information and education campaigns are mandatory among the general population and among the medical and paramedical staff to make progress on the management of epilepsy in developing countries.Keywords: Epilepsy, developing countries, antiepileptics drugs, treatment gap, stigma, patients.
Current Pharmaceutical Design
Title:Antiepileptic Treatments in Developing Countries
Volume: 23 Issue: 37
Author(s): Jeremy Jost*, Athanase Millogo and Pierre-Marie Preux
Affiliation:
- INSERM, Univ. Limoges, CHU Limoges, UMR_S 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, CNRS FR 3503 GEIST, F-87000 Limoges,France
Keywords: Epilepsy, developing countries, antiepileptics drugs, treatment gap, stigma, patients.
Abstract: Background: Epilepsy affects about 70 million people worldwide, nearly 90% of whom live in developing countries. Epilepsy is surrounded by myths and stigma in these countries. Discrimination and social stigmatization are difficult obstacles for patients to overcome. Knowledge, attitudes and practices towards epilepsy are often inadequate, even sometimes totally false and then dangerous.
Methods: The goal was to present the situation and analyse the determinants of using antiepileptic drugs in developing countries. Results: The treatment gap exceeds 75% in most low-income countries, and could be even higher in rural areas. Reasons for that are low accessibility, availability, and/or affordability, lack of trained medical personnel and the associated beliefs and stigma. The interactions between drugs or due to other factors, such as malnutrition, are frequent. A long-lasting treatment is not usual for populations in developing countries due to cultural beliefs. The traditional healers are the first ones consulted in such a context, then delaying the entry in the “modern” medical care system. Conclusion: Information and education campaigns are mandatory among the general population and among the medical and paramedical staff to make progress on the management of epilepsy in developing countries.Export Options
About this article
Cite this article as:
Jost Jeremy *, Millogo Athanase and Preux Pierre-Marie, Antiepileptic Treatments in Developing Countries, Current Pharmaceutical Design 2017; 23 (37) . https://dx.doi.org/10.2174/1381612823666170809103202
DOI https://dx.doi.org/10.2174/1381612823666170809103202 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Template Dependent Human DNA Polymerases
Current Topics in Medicinal Chemistry Editorial [ Hot Topic: Recent Advances in Pediatric Epilepsy Surgery (Guest Editor: Batool F. Kirmani)]
Current Pediatric Reviews Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain
Current Neuropharmacology Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome
Current Alzheimer Research Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance
Current Molecular Medicine Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Biodistribution Processes as Underestimated Confounders in Translational Stroke Research
Current Medicinal Chemistry Critical Role of the Endocannabinoid System in the Regulation of Food Intake and Energy Metabolism, with Phylogenetic, Developmental, and Pathophysiological Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-Antidepressant Pharmacologic Long-Term Treatment of Panic Disorder
Current Clinical Pharmacology GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) 5 Hz Repetitive Transcranial Magnetic Stimulation with Maximum Voluntary Muscle Contraction Facilitates Cerebral Cortex Excitability of Normal Subjects
CNS & Neurological Disorders - Drug Targets In Vitro Evaluation of Potential Hepatotoxicity Induced by Drugs
Current Pharmaceutical Design Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews The Need to Avoid the Routine Use of Episiotomy
Current Women`s Health Reviews The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design